BCR signaling is activated and BCL-2 expression increases in Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib-resistant CLL and DLBCL33,34. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.